For as much as the sell-side seems to complain about Amgen (Nasdaq:AMGN),
it doesn't seem to have resulted in the company missing out on the
run-up in biotech and pharma names over the last 12 to 18 months. With
uncertain risk from biosimilars and a pipeline
that strikes many investors as lackluster, Amgen isn't the easiest name
to like today, and the risk of the company overpaying for Onyx Pharmaceuticals (Nasdaq:ONXX)
doesn't help. On balance, it's difficult to work up a lot of enthusiasm
for Amgen at this price, but key clinical data in early 2014 could add
some solid support to the stock.
Please continue here:
http://www.investopedia.com/stock-analysis/073113/does-amgen-deserve-be-part-biotech-bull-run-amgn-onxx-azn-teva.aspx
No comments:
Post a Comment